Cargando…

The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis

OBJECTIVES: The rate of early neurological deterioration (END) occurring after thrombolytic therapy is controversial. To explore a more precise estimation of the rate, a meta‐analysis was conducted in the present study. METHODS: The relevant studies were identified by searching PubMed, EMBASE, and C...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xiaowen, Chen, Wanli, Xu, Haibin, Zhu, Zhi, Xu, Yuanyuan, Chen, Huisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379592/
https://www.ncbi.nlm.nih.gov/pubmed/30632308
http://dx.doi.org/10.1002/brb3.1210
_version_ 1783396121161236480
author Hou, Xiaowen
Chen, Wanli
Xu, Haibin
Zhu, Zhi
Xu, Yuanyuan
Chen, Huisheng
author_facet Hou, Xiaowen
Chen, Wanli
Xu, Haibin
Zhu, Zhi
Xu, Yuanyuan
Chen, Huisheng
author_sort Hou, Xiaowen
collection PubMed
description OBJECTIVES: The rate of early neurological deterioration (END) occurring after thrombolytic therapy is controversial. To explore a more precise estimation of the rate, a meta‐analysis was conducted in the present study. METHODS: The relevant studies were identified by searching PubMed, EMBASE, and Cochrane Collaboration Database up to June 2018. The definition of END was prespecified according to the most commonly used definition: ≥4‐point increase in National Institutes of Health Stroke Scale between admission and 24 hr. The meta‐analysis was performed by using the STATA 12. RESULTS: Eleven studies with a total of 3,539 subjects, including 373 patients with END and 3,166 patients without END, were collected. The pooled analysis showed that the rate of END occurring after thrombolytic therapy was about 11.0% (95% CI: 7.8%–14.3%). Subgroup analysis by continent showed that the rate of END occurring after thrombolytic therapy of patients in Asia (15.9%, 95% CI: 7.4%–24.5%) was higher than in Europe (7.6%, 95% CI: 4.9%–10.3%) and in North America (11.8%, 95% CI: 8.5%–15.0%). Subgroup analysis by onset to treatment time (OTT) displayed that the rate of END occurring after thrombolytic therapy was 5.4% (95% CI: 1.2%–9.5%), 15.6% (95% CI: 9.6%–21.5%), and 18.5% (95% CI: 11.2%–25.8%) for the patients whose OTT ≤120.0 min, from 120.1 to 179.9 min, from 180.0 to 270.0 min, respectively. CONCLUSION: The rate of END occurring after thrombolytic therapy is about 11.0%. This finding may provide a scientific reference for researchers to evaluate the efficacy and safety of thrombolytic therapy.
format Online
Article
Text
id pubmed-6379592
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63795922019-02-28 The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis Hou, Xiaowen Chen, Wanli Xu, Haibin Zhu, Zhi Xu, Yuanyuan Chen, Huisheng Brain Behav Original Research OBJECTIVES: The rate of early neurological deterioration (END) occurring after thrombolytic therapy is controversial. To explore a more precise estimation of the rate, a meta‐analysis was conducted in the present study. METHODS: The relevant studies were identified by searching PubMed, EMBASE, and Cochrane Collaboration Database up to June 2018. The definition of END was prespecified according to the most commonly used definition: ≥4‐point increase in National Institutes of Health Stroke Scale between admission and 24 hr. The meta‐analysis was performed by using the STATA 12. RESULTS: Eleven studies with a total of 3,539 subjects, including 373 patients with END and 3,166 patients without END, were collected. The pooled analysis showed that the rate of END occurring after thrombolytic therapy was about 11.0% (95% CI: 7.8%–14.3%). Subgroup analysis by continent showed that the rate of END occurring after thrombolytic therapy of patients in Asia (15.9%, 95% CI: 7.4%–24.5%) was higher than in Europe (7.6%, 95% CI: 4.9%–10.3%) and in North America (11.8%, 95% CI: 8.5%–15.0%). Subgroup analysis by onset to treatment time (OTT) displayed that the rate of END occurring after thrombolytic therapy was 5.4% (95% CI: 1.2%–9.5%), 15.6% (95% CI: 9.6%–21.5%), and 18.5% (95% CI: 11.2%–25.8%) for the patients whose OTT ≤120.0 min, from 120.1 to 179.9 min, from 180.0 to 270.0 min, respectively. CONCLUSION: The rate of END occurring after thrombolytic therapy is about 11.0%. This finding may provide a scientific reference for researchers to evaluate the efficacy and safety of thrombolytic therapy. John Wiley and Sons Inc. 2019-01-10 /pmc/articles/PMC6379592/ /pubmed/30632308 http://dx.doi.org/10.1002/brb3.1210 Text en © 2019 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Hou, Xiaowen
Chen, Wanli
Xu, Haibin
Zhu, Zhi
Xu, Yuanyuan
Chen, Huisheng
The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis
title The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis
title_full The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis
title_fullStr The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis
title_full_unstemmed The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis
title_short The rate of early neurological deterioration occurring after thrombolytic therapy: A meta‐analysis
title_sort rate of early neurological deterioration occurring after thrombolytic therapy: a meta‐analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379592/
https://www.ncbi.nlm.nih.gov/pubmed/30632308
http://dx.doi.org/10.1002/brb3.1210
work_keys_str_mv AT houxiaowen therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT chenwanli therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT xuhaibin therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT zhuzhi therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT xuyuanyuan therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT chenhuisheng therateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT houxiaowen rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT chenwanli rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT xuhaibin rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT zhuzhi rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT xuyuanyuan rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis
AT chenhuisheng rateofearlyneurologicaldeteriorationoccurringafterthrombolytictherapyametaanalysis